NasdaqGS - Delayed Quote USD

Amneal Pharmaceuticals, Inc. (AMRX)

5.87 -0.03 (-0.51%)
At close: 4:00 PM EDT
5.74 -0.13 (-2.21%)
After hours: 4:23 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,393,607.00
2,393,607.00
2,212,304.00
2,093,669.00
1,992,523.00
Cost of Revenue
1,573,042.00
1,573,042.00
1,427,596.00
1,324,696.00
1,364,130.00
Gross Profit
820,565.00
820,565.00
784,708.00
768,973.00
628,393.00
Operating Expense
596,315.00
596,315.00
595,786.00
575,067.00
517,312.00
Operating Income
224,250.00
224,250.00
188,922.00
193,906.00
111,081.00
Net Non Operating Interest Income Expense
-251,434.00
-251,434.00
-158,668.00
-136,325.00
-145,998.00
Other Income Expense
-13,086.00
-13,086.00
-278,381.00
-26,215.00
-863.00
Pretax Income
-40,270.00
-40,270.00
-248,127.00
31,366.00
-35,780.00
Tax Provision
8,452.00
8,452.00
6,662.00
11,196.00
-104,358.00
Net Income Common Stockholders
-83,993.00
-83,993.00
-129,986.00
10,624.00
91,059.00
Diluted NI Available to Com Stockholders
-83,993.00
-83,993.00
-129,986.00
10,624.00
91,059.00
Basic EPS
-0.48
-0.48
-0.86
0.07
0.62
Diluted EPS
-0.48
-0.48
-0.86
0.07
0.61
Basic Average Shares
176,136.00
176,136.00
150,944.00
148,922.00
147,443.00
Diluted Average Shares
176,136.00
176,136.00
150,944.00
151,821.00
148,913.00
Total Operating Income as Reported
204,374.00
204,374.00
-94,928.00
152,716.00
91,155.00
Total Expenses
2,169,357.00
2,169,357.00
2,023,382.00
1,899,763.00
1,881,442.00
Net Income from Continuing & Discontinued Operation
-83,993.00
-83,993.00
-129,986.00
10,624.00
91,059.00
Normalized Income
-69,611.05
-69,611.05
104,023.06
37,337.44
93,579.69
Interest Expense
210,629.00
210,629.00
158,377.00
136,325.00
145,998.00
Net Interest Income
-251,434.00
-251,434.00
-158,668.00
-136,325.00
-145,998.00
EBIT
170,359.00
170,359.00
-89,750.00
167,691.00
110,218.00
EBITDA
399,759.00
399,759.00
150,425.00
401,097.00
345,605.00
Reconciled Cost of Revenue
1,573,042.00
1,573,042.00
1,427,596.00
1,324,696.00
1,364,130.00
Reconciled Depreciation
229,400.00
229,400.00
240,175.00
233,406.00
235,387.00
Net Income from Continuing Operation Net Minority Interest
-83,993.00
-83,993.00
-129,986.00
10,624.00
91,059.00
Total Unusual Items Excluding Goodwill
-18,205.00
-18,205.00
-296,214.00
-41,545.00
-3,453.00
Total Unusual Items
-18,205.00
-18,205.00
-296,214.00
-41,545.00
-3,453.00
Normalized EBITDA
417,964.00
417,964.00
446,639.00
442,642.00
349,058.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-3,823.05
-3,823.05
-62,204.94
-14,831.57
-932.31
12/31/2020 - 5/7/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

EBS Emergent BioSolutions Inc.
1.9200
-1.54%
 
OPTN OptiNose, Inc.
0.8604
-4.93%
 
IRWD Ironwood Pharmaceuticals, Inc.
7.82
-3.22%
 
AQST Aquestive Therapeutics, Inc.
4.0700
+3.56%
 
EVO Evotec SE
5.02
-1.57%
 
LFCR Lifecore Biomedical, Inc.
6.60
-0.68%
 
NBIX Neurocrine Biosciences, Inc.
135.99
-1.28%
 
AVDL Avadel Pharmaceuticals plc
17.81
-0.06%
 
KMDA Kamada Ltd.
5.15
-0.96%
 
ESPR Esperion Therapeutics, Inc.
1.9000
-4.52%